alexa Search For Unknown Immunogenicity: An Overview
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

7th European Biosimilars Congress
May 15-16, 2017 Munich, Germany

Rosa Helena Bustos Cruz
University of La Sabana, Colombia
ScientificTracks Abstracts: J Bioanal Biomed
DOI: 10.4172/1948-593X-C1-026
Abstract
The scope of this speech is to show a general consideration regarding the evaluation of immunogenicity in bio-therapeutic products. Biological drugs and their biosimilars are highly complex molecules derived from living cells or organisms. The success of biological drugs has been focused on unwanted immunogenicity of these products. Evaluation of unwanted immunogenicity is an important consideration in development of bio-therapeutics products. Immunogenicity to protein based biological drugs is a complex process that involves numerous factors such as general patient´s immunity, amino-acid sequence of proteins, as well as biological drugs formulation (i.e. protein aggregates, impurities or excipients improper choice) and the drug administration. With new platforms, new technologies and development of novel therapeutics and treatment modalities, the assessment of immunogenicity will continue to require products approved on safety as well as on efficacy perspectives. Correlation between immunogenicity and clinical sequelae entirely depends on the appropriate detection, measurement and characterization of antibodies against biological therapeutics. These include conventional approaches such as ELISA and radioimmunoprecipitation assays. Alternative technologies use instruments based in nanobiosensors as surface plasmon resonance (SPR) and quartz crystal microbalances (QCM) to detect and characterize antibodies against therapeutic proteins and other molecular interactions. The purpose of this presentation is to show a general overview on the ability to detect therapeutic induced antibodies in plasma and sera of treated patients with biological drugs, using nanobiosensors. The evaluation, safety and efficacy of biosimilars require more rigorous testing than conventional generic drugs. The profiles of biosimilars must demonstrate similar physicochemical and biological characteristics, efficacy and safety in accordance with the approval requirements of regulatory authorities.
Biography

Rosa Helena Bustos Cruz works on nanobiosensors development for evaluation and characterization of molecular interaction in biological drugs. She introduced the nanobiosensors (surface plasmon resonance and quartz crystal microbalance) as new research technology in Colombia. She is also the Group Leader of Therapeutic Evidence Group at Universidad de La Sabana. She and her group works on safety and efficacy in drugs, clinical pharmacology and pharmacovigilance. She has also participated in the elaboration of evaluation guidelines for biosimilars according to regulatory affair (INVIMA).

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords